| | | | | Israeli pharmaceuticals company PainReform has received approval from the U.S. Food and Drug Administration (FDA) to begin late-stage clinical studies for a pain relief drug that is a departure from opiate-based narcotics, it said on Tuesday. | | |
| | | (Reuters Health) - Hormones given to people to align their sex with their gender pose a significant risk of serious blood clots and stroke among transgender women, one of the largest studies of transgender patients has concluded. | | |
| | | U.S. President Donald Trump on Monday took aim at Pfizer Inc and other U.S. drugmakers after they raised prices on some of their medicines on July 1, saying his administration would act in response. | | |
| | | (Reuters Health) - After a cardiac arrest in the hospital, older black patients don't survive as long as older white patients, new data show. | | |
| | | French food group Danone is investigating reports that its new Aptamil baby milk formula has made some infants unwell in Britain. | | |
| | | (Reuters Health) - Social behavior in the operating room is significantly affected by the mix of professional roles and the surgeon's gender, according to researchers who observed 200 surgical procedures. | | |
| | | CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent. | | |
| | | Health insurers warned that a move by the Trump administration on Saturday to temporarily suspend a program that was set to pay out $10.4 billion to insurers for covering high-risk individuals last year could drive up premium costs and create marketplace uncertainty. | | |
| | | The Trump administration on Saturday halted billions of dollars in payments to health insurers under the Obamacare healthcare law, saying that a recent federal court ruling prevents the money from being disbursed. | | |
| | | (Reuters Health) - People who get diagnosed with cancer may be more likely to develop diabetes, a Korean study suggests. | | |
| | | Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | | |
|
| |
